Class 4 Medicines Defect Notification: Doncaster Pharma Limited, Hiprex 1g tablets, EL(26)A/20
UKClass 4 Medicines Defect Notification: Doncaster Pharma Limited, Hiprex 1g tablets, EL(26)A/20
Recalling Firm: Doncaster Pharma Limited
Reason for Recall / Hazard
Doncaster Pharma Limited has informed the MHRA of an error related to the Braille embossing on the outer packaging of certain parallel imported batches of Hiprex 1 g tablets (POM)....
Product Description & Identification
Doncaster Pharma Limited has informed the MHRA of an error related to the Braille embossing on the outer packaging of certain parallel imported batches of Hiprex 1 g tablets (POM).
Affected Products
Class 4 Medicines Defect Notification: Doncaster Pharma Limited, Hiprex 1g tablets, EL(26)A/20
Additional Source Details
| Field | Value |
|---|---|
| Guid | tag:www.gov.uk,2005:/drug-device-alerts/class-4-medicines-defect-notification-doncaster-pharma-limited-hiprex-1g-tablets-el-26-a-slash-20 |
| Link | https://www.gov.uk/drug-device-alerts/class-4-medicines-defect-notification-doncaster-pharma-limited-hiprex-1g-tablets-el-26-a-slash-20 |
| Pub Date | 2026-04-22T11:00:22+01:00 |
| Extracted category | drugs |
Overview
- Recalling FirmDoncaster Pharma Limited
- Risk LevelMedicines Recall
- DistributionUnited Kingdom
📢 Share Warning
Alert family and friends to keep them safe. Copy this quick alert message:
🚨 SAFETY ALERT: Doncaster Pharma Limited - Class 4 Medicines Defect Notification: Doncaster Pharma Limited, Hiprex 1g tablets, EL(26)A/20 Check if your household is affected: https://therecallfile.com/recalls/class-4-medicines-defect-notification-doncaster-pharma-limited-hiprex/UK-MHRA-class-4-medicines-defect-notification-doncaster-pharma-limited-hiprex-1g-tablets-el-26-a-slash-20
Join Alertlist
Get instant email updates whenever critical safety recalls like this are published.
Related Recalls
UKClass 4 Medicines Defect Notification: Neuraxpharm UK Ltd, Tuzulby prolonged-release chewable tablets, EL(26)A/36
Class 4 Medicines Defect Notification: Neuraxpharm UK Ltd, Tuzulby prolonged-release chewable tablets, EL(26)A/36
Neuraxpharm UK Ltd has informed the MHRA of missing safety information in the Patient Information Leaflet (PIL) and Summary of Product Characteristics (SmPC) for certain batches of Tuzulby prolonged r...
AustraliaGLP-1 RAs and rare, but severe, eye disorders
GLP-1 RAs and rare, but severe, eye disorders
Product warnings across the GLP-1 RA class of medicines have been updated due to the potential for these products to cause a rare, but severe, form of eye disorder....
UKClass 4 Medicines Defect Notification: Macarthys Laboratories Ltd T/A Martindale Pharma, Xaggitin XL Prolonged-release Tablets, EL(26)A/35
Class 4 Medicines Defect Notification: Macarthys Laboratories Ltd T/A Martindale Pharma, Xaggitin XL Prolonged-release Tablets, EL(26)A/35
Macarthys Laboratories Ltd T/A Martindale Pharma has notified the MHRA of a manufacturing issue impacting several batches of Xaggitin XL Prolonged-release Tablets, due to the occurrence of incorrect t...